揭示帕博利珠单抗联合恩杂鲁胺治疗尿路上皮癌患者活性的潜在机制。
Unlocking the mechanisms underlying the activity of pembrolizumab plus enfortumab vedotin in patients with urothelial carcinoma.
作者信息
Santoni Matteo, Rizzo Alessandro, Massari Francesco
机构信息
Oncology Unit, Macerata Hospital, via Santa Lucia 2, Macerata, Italy.
Struttura S.S.D.C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori "Giovanni Paolo II, Bari, Italy.
出版信息
Expert Opin Investig Drugs. 2025 Apr;34(4):259-265. doi: 10.1080/13543784.2025.2473695. Epub 2025 Feb 28.
INTRODUCTION
Urothelial carcinoma (UC) is frequently associated with a poor prognosis in patients with advanced disease. A strong biological rationale supports the investigation of combining antibody-drug conjugates (ADCs) with immunotherapy to overcome the occurrence of resistance and improve patient outcomes.
AREAS COVERED
In this review, we illustrate the mechanisms of action of pembrolizumab and enfortumab vedotin (EV) and the immune and biological rationales underlying their synergy in mUC patients.
EXPERT OPINION
The results of the combination of EV and pembrolizumab represent a ray of light in the therapeutic scenario of mUC patients. A deeper understanding of the mechanisms underlying the synergistic effects of these agents will be crucial to reduce drug-resistance and further improve the outcome of mUC patients.
引言
尿路上皮癌（UC）在晚期疾病患者中常常预后不良。一个强有力的生物学理论依据支持对抗体药物偶联物（ADC）与免疫疗法联合使用进行研究，以克服耐药性的发生并改善患者预后。
涵盖领域
在本综述中，我们阐述了帕博利珠单抗和恩沃利单抗（EV）的作用机制以及它们在转移性尿路上皮癌（mUC）患者中协同作用的免疫和生物学理论依据。
专家观点
EV与帕博利珠单抗联合使用的结果为mUC患者的治疗前景带来了一线曙光。深入了解这些药物协同作用的潜在机制对于降低耐药性和进一步改善mUC患者的预后至关重要。
Zotero 插件